Drug Trial Radar · NCT04382053
Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia
Last checked: Nov 19, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
143
Actual
Start
May 27, 2020
Primary completion
Dec 10, 2020
Study completion Dec 24, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study was designed to assess the efficacy and safety of DFV890 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.
Conditions
- COVID-19 Pneumonia, Impaired Respiratory Function
Interventions
DFV890Drug
DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
Standard of Care (SoC)Drug
SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Primary outcomes
What the sponsor says the trial is designed to measure.
- APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)Time frame: up to Day 15
Locations
29 sites in 12 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Hvidovre, Denmark
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
New Delhi, India
Novartis Investigative Site
New Delhi, India
Novartis Investigative Site
Coimbatore, Tamil Nadu, India
Novartis Investigative Site
Kolkata, West Bengal, India
Novartis Investigative Site
Mexico City, Mexico CP, Mexico
Novartis Investigative Site
Monterrey, Nuevo León, Mexico
Novartis Investigative Site
Harderwijk, Netherlands
Novartis Investigative Site
San Martín de Porres, Lima region, Peru
Novartis Investigative Site
San Miguel, Lima region, Peru
Novartis Investigative Site
Barnaul, Russia
Novartis Investigative Site
Chelyabinsk, Russia
Novartis Investigative Site
Krasnoyarsk, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Ryazan, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Yekaterinburg, Russia
Novartis Investigative Site
George, Western Cape, South Africa
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.